The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that ...

Palantir stock rises on the back of better-than-expected quarterly earnings and a solid first-quarter outlook.

COPENHAGEN, Feb 3 () - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% this year ...

Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly ...

Novo Nordisk’s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its ...

Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.